FDA approves faricimab for treatment of wet AMD and DME

Faricimab will be the first and only FDA-approved medicine targeting two distinct pathways, Ang-2 and VEGF-A, involved in retinal diseases and may cause vision loss. To see the Angiogenesis Foundation’s educational resources on Ang-2, please visit The Science of...